1. Home
  2. Food
  3. News & Events from HFP
  4. Workshops, Meetings & Webinars on Food and Dietary Supplements
  5. Public Meeting on the Development of an Enhanced Systematic Process for FDA’s Post-Market Assessment of Chemicals in Food - 09/25/2024
  1. Workshops, Meetings & Webinars on Food and Dietary Supplements

Meeting | Mixed

Event Title
Public Meeting on the Development of an Enhanced Systematic Process for FDA’s Post-Market Assessment of Chemicals in Food
September 25, 2024

Date:
September 25, 2024

On May 12, 2026, the FDA finalized its food chemical safety post-market assessment program, releasing two documents that establish the FDA’s proactive, science-based framework for reviewing chemicals present in the U.S. food supply. Visit FDA’s new webpage, Understanding the FDA’s Systematic Process for Ensuring the Post-Market Safety of Chemicals in Food, for additional information. 

Background

The FDA is developing a systematic process for conducting post-market assessments of chemicals in food. This includes ingredients considered generally recognized as safe (GRAS), food additives, color additives, food contact substances, and contaminants. This is intended to guide our post-market assessment work going forward and includes a transparent process for identifying and prioritizing food chemicals currently in the market for safety reviews. This project is part of a larger enhanced approach for food chemical safety.

The FDA hosted a public meeting to share the agency’s enhanced systematic process for post-market assessment of chemicals in food and hear stakeholder perspectives on this proposal. This information helped inform our thinking and further the development of the process.

Meeting Information

The FDA hosted this public meeting on Wednesday, September 25, 2024, from 12:30 – 5:30 PM ET. The meeting was held in-person at the FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, MD 20993 with an option for virtual participation as well.

Meeting Recording

Public Meeting Transcript

Public Comments

View submitted comments in the docket folder FDA-2024-N-3609

We invited interested persons, including those participating in the public meeting, to provide information on topics related to the process outlined in the discussion paper. In particular, we welcomed feedback on the following questions.

Related Resources


Back to Top